A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 160 participants.

Also called NCT02081690

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02081690
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
France, Italy, Spain (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02081690. Allocation not applicable; no masking; primary purpose treatment. Start 2014-03-01 (actual); primary completion 2015-10-01 (actual). Results posted on 2018-02-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Acronym
ORCHESTRA
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Macitentan
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct02081690
Content hash
df5f53653e80655e8cc32a5e1f6a9ea30c027a189f069f034c8d3097553f198a